Key result
TAVR matches SAVR survival with faster recovery across all surgical risk groups in severe AS.
Why the study?
TAVR has transformed the management of severe aortic stenosis across all surgical-risk categories, warranting a summary of current indications, pre-procedural evaluation, outcomes, and special considerations in access disparities, high-risk comorbid populations, antiplatelet strategies, and vascular complications.
Does transcatheter aortic valve replacement (TAVR) improve survival, stroke, and quality-of-life outcomes compared to surgical aortic valve replacement (SAVR) in adults with severe aortic stenosis across surgical risk categories and special populations?
Does transcatheter aortic valve replacement (TAVR) improve survival, stroke, and quality-of-life outcomes compared to surgical aortic valve replacement (SAVR) in adults with severe aortic stenosis across surgical risk categories and special populations?
This narrative review synthesizes trial and guideline evidence confirming TAVR's comparability to SAVR across surgical risk strata while highlighting critical management considerations regarding geographic access delays, COPD severity, avoidance of pre-procedural DAPT to reduce bleeding, and anatomical planning to prevent vascular complications.
Answers are grounded in this paper and cite their sources.
Supports TAVR across risk strata for faster recovery; confirms prior RCTs and extends guideline synthesis to 2025.
Introduction Severe aortic stenosis is a prevalent and life-threatening disease among older adults. Transcatheter aortic valve replacement (TAVR) has transformed management across all surgical-risk categories, supported by clinical trial data and guideline recommendations. This review aims to summarize current indications, pre-procedural evaluation, and clinical outcomes of TAVR, and to highlight special considerations in access disparities, high-risk comorbid populations, antiplatelet strategies, and vascular complications. Methods This narrative review synthesizes guideline documents, landmark randomized trials, and selected meta-analyses published between 2010 and 2025. Additional focused evidence from four retrospective cohort studies was used to illustrate issues in geographic access, chronic obstructive pulmonary disease (COPD), dual antiplatelet therapy (DAPT), and vascular access complications. Results Guideline-directed criteria increasingly support TAVR across age and surgical-risk groups, with transfemoral access demonstrating the most favorable outcomes. Randomized trials consistently show comparable survival between TAVR and surgical aortic valve replacement (SAVR), with faster early recovery and improved early quality-of-life metrics. Complication profiles differ: TAVR reduces bleeding and atrial fibrillation but increases vascular injury, conduction disturbances, and paravalvular regurgitation. Special populations—including those with advanced COPD or remote geographic residence—derive meaningful benefit. DAPT before TAVR increases bleeding and may worsen survival, whereas vascular complications significantly affect early outcomes and are strongly predicted by anatomical factors such as sheath-to-femoral artery ratio. Conclusions TAVR provides excellent short- and mid-term outcomes for appropriately selected patients. Continued attention to anatomical planning, pre-procedural optimization, and equitable access, along with long-term surveillance of valve durability, will shape future patient selection and procedural refinement.
No takes yet. Share an insight, caveat, or question.
Antes et al. (2026) conducted a review in Severe aortic stenosis. Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated. Transcatheter aortic valve replacement provides comparable survival to surgical aortic valve replacement with faster recovery across all surgical-risk categories in severe aortic stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: